論文・技術情報追加のお知らせ

1. Fluoroquinolones and risk of nightmares: A literature review and disproportionality analysis using individual case safety reports from Food and Drug Administration Adverse Event Reporting System database.

ニューキノロン系薬剤が悪夢のリスク増加に関連

対象DB：FAERS

2. Adverse event profiles of four monomethyl auristatin E-conjugated antibody drug conjugates: a disproportionality analysis based on the US FDA adverse event reporting system (FAERS) database.

MMAE-ADC関連有害事象の解析と安全性評価

対象DB：FAERS

3. Identifying Predictors of Serious Adverse Events in Antidepressant Treatment from a Decade-Long Nationwide Pharmacovigilance Study: Impact of Dementia and Parkinson's Disease Treatment.

抗うつ薬関連重大有害事象の予測因子解析

対象DB：FAERS,KAERS

4. Explaining Uncertain Hepatoprotective Effects: When Silibinin Co-Administered with Other Drugs.

シリビニン併用で肝毒性リスク増加の可能性

対象DB：FAERS

5. Towards interpretable drug interaction prediction via dual-stage attention and Bayesian calibration with active learning.

DABI-DDIでDDI予測と生物学的解釈向上

対象DB：FAERS

6. Drug adverse events associated with temozolomide administration: A real-world pharmacovigilance study using the FAERS database from 2014 to 2024.

テモゾロミドの副作用解析と新規AE特定

対象DB：FAERS

7. Malignant melanoma and multiple sclerosis therapies: A disproportionality analysis of the FDA adverse event reporting system.

MS治療薬が悪性黒色腫リスクに影響の可能性

対象DB：FAERS

8. The Association Between Dexmedetomidine and Bradycardia: An Analysis of FDA Adverse Event Reporting System (FAERS) Data and Transcriptomic Profiles.

デクスメデトミジンの徐脈リスクと遺伝子解析

対象DB：FAERS

9. SGLT2 inhibitors may increase creatinine clearance: data mining utilizing the FDA Adverse Event Report System database and pharmacokinetic study with rats.

SGLT2阻害薬がクレアチニン排泄量を増加可能性

対象DB：FAERS

10. Real-world pharmacovigilance reports of hepatitis A inactivated and hepatitis B (recombinant) vaccine: insights from disproportionality analysis of the vaccine adverse event reporting system.

HepABワクチンの副作用を総合的に解析評価

対象DB：FAERS,VAERS

11. A real-world pharmacovigilance study of lorazepam based on the FDA adverse event reporting system database.

ロラゼパムの安全性評価と新規副作用解析

対象DB：FAERS

12. Safety evaluation of irinotecan: a real-world disproportionality analysis using FAERS and JADER databases during the time period 2004-2024.

イリノテカンの副作用を地域別に比較解析

対象DB：FAERS,JADER

13. An integrated approach based on FDA adverse event reporting system, network pharmacology, molecular docking, and molecular dynamics simulation analysis to study the cardiac adverse reactions and mechanism of action of osimertinib.

オシメルチニブの心毒性と分子機序を解明

対象DB：FAERS

14. Postmarketing safety analysis of remimazolam: Identifying unlabelled serious events.

レミマゾラムの安全性評価と副作用解析

対象DB：FAERS,JADER

15. Adverse events associated with gepants: a pharmacovigilance analysis based on the FDA adverse event reporting system.

Gepantsの副作用リスク信号を体系的に解析

対象DB：FAERS

16. Association Between Melatonin Receptor Agonists and Cardiac Arrhythmia; Disproportionality Analysis Studies Using Pharmacovigilance Databases.

メラトニン受容体作動薬と心不整脈の関連評価

対象DB：FAERS

17. Beyond pain relief: the thrombosis threat of celecoxib.

セレコキシブと血栓症のリスクと因果関係解析

対象DB：CVAR,FAERS,JADER

18. Comprehensive Analysis of Proteinuria and Nephrotic Syndrome Using the Japanese Adverse Drug Event Reporting Database.

抗VEGF薬と蛋白尿・ネフローゼ症候群の関連解析

対象DB：JADER

19. Risk Factors Associated With Thrombocytopenia Induced by Intravenous Immunoglobulin Formulations: An Analysis Using the JADER database.

IVIgによる血小板減少症のリスクと関連要因評価

対象DB：JADER

20. JADER Database-based Analysis of the Association Between Tranexamic Acid and Thromboembolism and Related Risk Factors.

TXAと静脈血栓塞栓症の関連性をRWDで評価

対象DB：JADER

21. Time-to-Onset Analysis of Rhabdomyolysis Associated With Selective Serotonin and Serotonin-Noradrenaline Reuptake Inhibitors Using the Japanese Pharmacovigilance Database.

SSRI/SNRIと横紋筋融解症の関連と発症時期解析

対象DB：JADER

22. Vonoprazan-associated Microscopic Colitis and Continued Use After Onset: A Study Using a Japanese Pharmacovigilance Database.

ボノプラザンと顕微鏡的大腸炎の関連解析

対象DB：JADER

23. Analysis of Esophageal Ulcers Using the Japanese Adverse Drug Event Report Database.

薬剤性食道潰瘍の原因薬と発症特性解析

対象DB：JADER

24. Severe drug-associated anaphylaxis: a complementary descriptive analyses of registry cases and spontaneous reports.

薬剤誘発重度アナフィラキシーの分析と要因確認

対象DB：EudraVigilance

25. Quality of Clinical Information in Pregnancy Pharmacovigilance Data Sources-A Contribution of the ConcePTION Project.

妊娠中の薬物曝露データの臨床品質評価

対象DB：EudraVigilance

26. Comparative Pharmacovigilance Analysis of Approved and Repurposed Antivirals for COVID-19: Insights from EudraVigilance Data.

COVID-19抗ウイルス薬の安全性比較分析

対象DB：EudraVigilance

27. Uncovering Pregnancy Exposures in Pharmacovigilance Case Report Databases: A Comprehensive Evaluation of the VigiBase Pregnancy Algorithm.

VigiBase妊娠アルゴリズムの評価と成果解析

対象DB：VigiBase

28. Analysis of adverse events with ruxolitinib using real-world datasets and drug-interaction networks.

ルキソリチニブ副作用と遺伝子相互作用解析

対象DB：JADER

29. Regional Disparities in Incidence, Therapeutic Approaches, and In-hospital Mortality of Critical Limb Ischemia in Japan.

日本における重症虚血肢の地域格差分析

対象DB：DPC

30. Measuring frailty: a comparison of the cumulative deficit model of frailty in survey and routine data.

高齢者における調査・ルーチンデータ間のフレイル比較

対象DB：CPRD

31. Metformin to treat breast cancer: An application of the prevalent new-user design for observational studies with no active comparator.

メトホルミンと乳癌死亡率の不死時間バイアス分析

対象DB：CPRD

32. Incidence rates of bullous pemphigoid, herpes zoster, and urticaria following the start of the COVID-19 vaccination programme in the UK: a population-based cohort study.

COVID-19ワクチン後の皮膚疾患発生率分析

対象DB：CPRD

33. Long-term nitrofurantoin use: risks and alternatives in general practice.

長期ニトロフラントイン使用のリスクと代替策

対象DB：CPRD

34. Trends of long-term opioid therapy and subsequent discontinuation among people with chronic non-cancer pain in UK primary care: A retrospective cohort study.

慢性非がん痛への長期オピオイド療法傾向分析

対象DB：CPRD

35. Patterns of antidepressant prescribing around pregnancy: a descriptive analysis in CPRD.

妊娠中の抗うつ薬処方と使用状況の増加分析

対象DB：CPRD

36. Mortality and hospital admissions in people with eating disorders: longitudinal cohort study in secondary care-linked English primary care records.

摂食障害の死亡率と入院率の不均衡分析

対象DB：CPRD

37. The legacy effect of early HbA1c control on microvascular complications and hospital admissions in type 2 diabetes: findings from a large UK study.

2型糖尿病のHbA1c目標値と合併症リスク分析

対象DB：CPRD

38. Quantifying all-cause healthcare resource utilization and costs of children with mild-to-moderate long COVID in France.

小児ロングCOVIDの医療経済的負担の分析

対象DB：THIN

39. Use of GLP-1 receptor agonists and risks of suicide attempts or self-harm in patients with type 2 diabetes: a multicountry self-control case series study.

GLP-1受容体作動薬使用と自傷リスク調査

対象DB：THIN

40. Comparative effectiveness and prescribing trends of modified release versus immediate release indapamide in patients with hypertension: cohort study.

インダパミド処方動向と効果比較調査

対象DB：THIN

41. Sex Differences in Electrolyte Disturbances Among Diuretic Users According to Renal Function and Age.

利尿薬による電解質異常の性別・腎機能影響調査

対象DB：DeSC

42. Impact of 2014 Japanese practice guidelines on treatment patterns in patients with myasthenia gravis: an insurance claims database study.

重症筋無力症治療におけるステロイド使用変化調査

対象DB：DeSC